Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 28, 2011 Brian Orelli	Arena's Obese To-Do List The Food and Drug Administration's laundry list for Arena Pharmaceuticals seems to be getting longer.
The Motley Fool October 25, 2010 Brian Orelli	Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know.
The Motley Fool August 3, 2011 Brian Orelli	Arena Sheds a Few Pounds Off Its To-Do List The brain cancer issue seems to be rat specific.
The Motley Fool December 30, 2011 Brian Orelli	Working Through the Obese To-Do List in 2011 Arena ends the year on an upswing.
The Motley Fool September 17, 2010 Brian Orelli	Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile.
The Motley Fool September 14, 2010 Brian Orelli	42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
The Motley Fool October 19, 2010 Brian Orelli	Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency.
The Motley Fool November 9, 2010 Brian Orelli	Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over.
The Motley Fool January 4, 2012 Brian Orelli	This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval.
The Motley Fool December 22, 2010 Matt Koppenheffer	Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume.
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool May 27, 2011 Brian Orelli	Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug.
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool March 18, 2008 Brian Orelli	Lack of Side Effects Doesn't Fatten Arena Good safety data on its obesity drug fails to plump up Arena's stock price. Investors, take note.
The Motley Fool December 3, 2010 Brian Orelli	Obesity Drug Companies Are (Still) Risky Orexigen heads before an FDA panel.
The Motley Fool December 8, 2010 Brian Orelli	Up 100% With Room to Fly Orexigen gets a positive FDA panel nod.
The Motley Fool July 13, 2010 Brian Orelli	A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight.
The Motley Fool September 16, 2010 Brian Orelli	Abbott's Product Line May Get Thinner Not that it needs the obesity drug.
The Motley Fool March 30, 2011 Brian Orelli	This Share Count Might Need Some Obesity Meds Soon Arena gets some dilutive financing.
The Motley Fool July 16, 2010 Brian Orelli	Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool September 18, 2009 Brian Orelli	Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug.
The Motley Fool September 21, 2010 Brian Orelli	Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out.
The Motley Fool February 1, 2011 Brian Orelli	Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon.
The Motley Fool September 21, 2011 Brian Orelli	Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool September 2, 2010 Luke Timmerman	Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical.
The Motley Fool January 11, 2012 Dan Caplinger	Has Arena Pharmaceuticals Become the Perfect Stock? Since we looked at Arena Pharmaceuticals last year revenue has fallen back and debt-to-equity levels have soared.
The Motley Fool June 3, 2011 Luke Timmerman	Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold The close attention paid to safety makes this drug difficult to get right.
The Motley Fool November 23, 2009 Brian Orelli	The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs.
The Motley Fool July 14, 2010 Luke Timmerman	Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug
The Motley Fool July 2, 2010 Brian Orelli	Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get?
The Motley Fool September 2, 2010 Brian Orelli	Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them.
The Motley Fool July 16, 2010 Luke Timmerman	Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics.
The Motley Fool July 20, 2007 Brian Orelli	Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit.
The Motley Fool April 5, 2011 Brian Orelli	Obese Expectations Trump Great Data Sorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly.
Chemistry World September 17, 2010 Andrew Turley	Obesity drugs strive for US approval Could 2010 yet be the year of the obesity drug? At first glance the signs are promising. Regulators in the US will soon decide whether to allow three new contenders onto this attractive market.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool June 1, 2011 Brian Orelli	Not All "Regulatory Updates" Are the Good Kind Orexigen gives an update; investors update their holdings.
The Motley Fool September 9, 2009 Brian Orelli	Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa
Chemistry World June 28, 2012 Patrick Walter	FDA green lights new obesity drug Lorcaserin, which has been developed by US-based Arena Pharmaceuticals, in conjunction with Japan's Eisai, is the first obesity prescription medicine approved for 13 years.
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
The Motley Fool May 4, 2011 Brian Orelli	VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool November 7, 2008 Brian Orelli	Thinning Out the Pipeline The FDA says no to diet drugs from Sanofi-Aventis and Pfizer.
The Motley Fool July 16, 2010 Jordan DiPietro	Why Did These Stocks Plunge? A look at the prior day's biggest losers: Orexigen... Arena Pharmaceuticals... DragonWave...
The Motley Fool November 12, 2010 Brian Orelli	Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week.
The Motley Fool December 12, 2008 Brian Orelli	The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success?